Close Menu

Personalis

The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.

The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.

The company attributed much of the increase to its work with the VA’s Million Veteran Program, which made up three quarters of its earnings in the quarter.

Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs. 

Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.

The company hopes to convert biopharma customers to increasingly comprehensive approaches, and intends to branch out further with blood-based exome sequencing next year.

The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.

The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.